Phase i study of oral rigosertib (ON 01910.NA), a dual inhibitor of the PI3K and PLK1 pathways, in adult patients with advanced solid malignancies

Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella-Garcia, Brian W. Vogler, Stephen B. Keysar, Elizabeth Freas, Dara L. Aisner, Chen Ren, Aik Chook Tan, Francois Wilhelm, Manoj Maniar, S. Gail Eckhardt, Wells A. Messersmith, Antonio Jimeno

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase i study of oral rigosertib (ON 01910.NA), a dual inhibitor of the PI3K and PLK1 pathways, in adult patients with advanced solid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences